Interview with Hiro Fukutomi, Managing Director, Takeda UK
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Address: 436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
UK,United Kingdom
Tel: +44 (0)1223 226200
Web: http://astx.com/
Astex is the world leader in fragment based drug discovery – the most important advance in drug discovery chemistry in the last 20 years.
Our internal pipeline is currently focused on the discovery and development of products in the therapeutic areas of oncology and virology.
Our pre-eminent position in this field is underlined by:
The productivity of our discovery engine which has helped to deliver seven novel drug candidates into development – five of which are now in clinical trials with another two in preclinical development.
Multiple collaborations in various therapeutic areas with leading pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica and Novartis that collectively have headline potential deal value in excess of $1 billion for Astex.
World-class science that has been published in leading journals such as Nature, Science and the Journal of Medicinal Chemistry, with some of our papers being among the most cited in their field.
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
See our Cookie Privacy Policy Here
